Formulation considerations for dry powder inhalers

Therapeutic Delivery

Volumn 5, Issue 6, 2014, Pages 675-689

  Cordts, Eike ^a   Steckel, Hartwig ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; DRUG CARRIER; EXCIPIENT; FORMOTEROL; LACTOSE; RECOMBINANT HUMAN INSULIN; TOBRAMYCIN;

ADHESIVE MIXTURE; AIRFLOW; ASTHMA; BLENDING; BLISTER PACK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION PRODUCT; CRYSTALLIZATION; CYSTIC FIBROSIS; DISPOSABLE EQUIPMENT; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MIXTURE; DRUG PACKAGING; DRUG STORAGE; DRY POWDER; DRY POWDER INHALER; FILLING; FLOW RATE; FREEZE DRYING; HUMIDITY; LUNG INFECTION; METERED DOSE INHALER; MICRONIZATION; MOISTURE; PAIN; PARTICLE SIZE; PEAK INSPIRATORY FLOW; POWDER FLOW; PRIORITY JOURNAL; REVIEW; SINGLE DOSE DEVICE; SPHERONIZATION; SPRAY DRYING; SPRAY FREEZE DRYING; SUPERCRITICAL FLUID; TUBERCULOSIS; VACCINATION; WETTABILITY;

CHEMISTRY, PHARMACEUTICAL; DRY POWDER INHALERS; HUMANS; HUMIDITY; PARTICLE SIZE;

EID: 84905509430     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.35     Document Type: Review

References (107)

1. Anderson SD, Rozea PJ, Dolton R, Lindsay DA. Inhaled and oral bronchodilator therapy in exercise induced asthma. Aust. NZ J. Med. 5(6), 544-550 (1975).
2. Shaw RJS, Waller JF, Hetzel MR, Clark TJH. Do oral and inhaled terbutaline have different effects on the lung? Br. J. Dis. Chest 76(0), 171-176 (1982).
3. Onoue S, Yamada S. Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system? Ther. Deliv. 4(8), 887-889 (2013).
4. Global Initiative for Asthma (GINA). From the Global Strategy for Asthma Management and Prevention. www.ginasthma.org
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. www.goldcopd.org
6. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 588-599 (2003).
7. Kamin W, Erdnüss F, Krämer I. Inhalation solutions -which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers -update 2013. J. Cyst. Fibros. 13(3), 243-250 (2013).
8. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 97(6), 1327 (1990).
9. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur. J. Pharm. Sci. 19(5), 443-455 (2003).
10. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad. Med. 20(6), 667-673 (1956).
11. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care 50(9), 1139-1150 (2005).
12. Khassawneh BY, Al-Ali MK, Alzoubi KH et al. Handling of inhaler devices in actual pulmonary practice: metereddose inhaler versus dry powder inhalers. Respir. Care 53(3), 324-328 (2008).
13. Baverstock M, Woodhall N, Maarman V. P94 Do healthcare professionals have sufficient knowledge of inhaler techniques in order to educate their patients effectively in their use? Thorax 65(Suppl. 4), A117 (2010).
14. Price D, Bosnic-Anticevich S, Briggs A et al. Inhaler competence in asthma: Common errors, barriers to use and recommended solutions. Respir. Med. 107(1), 37-46 (2013).
15. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int. J. Chronic Obstruct. Pulm. Dis. 3(4), 763-770 (2008).
16. Newman SP. Spacer Devices for Metered Dose Inhalers. Clin. Pharmacokinet. 43(6), 349-360 (2004).
17. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J. Aerosol Med. 18(3), 264-272 (2005).
18. Bell JH, Hartley PS, Cox JSG. Dry powder aerosols I: A new powder inhalation device. J. Pharm. Sci. 60(10), 1559-1564 (1971).
19. Fisons Limited: US4161516 A (1979).
20. Astra Aktlebolag: US005551489A (1994).
21. Pharmatech GmbH: US 2011/0159102 A1 (2008).
22. Schuster A, Haliburn C, Doring G, Goldman MH. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 68(4), 344-350 (2013).
23. Boer De AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. Eur. J. Pharm. Sci. 28(3), 171-178 (2006).
24. Hoppentocht M, Hagedoorn P, Frijlink HW, Boer De AH. Design and development of a disposable high dose dry powder inhaler for aminoglycosides. Presented at: Drug Delivery To The Lungs 24: Proceedings. Edinburgh, UK, 11-13 December 2013.
25. Young PM, Crapper J, Philips G, Sharma K, Chan H, Traini D. Overcoming dose limitations using the Orbital® multibreath dry powder inhaler. J. Aerosol Med. Pulm. Drug Deliv. 27(2), 138-147 (2014).
26. Hoppentocht M, Hagedoorn P, Frijlink HW, Boer De AH. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur. J. Pharm. Biopharm. 86(1), 23-30 (2013).
27. Carvalho TC, Peters JI, Williams III RO. Influence of particle size on regional lung deposition -what evidence is there? Int. J. Pharm. 406(1-2), 1-10 (2011).
28. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of 2-agonist particle size. Am. J. Respir. Crit. Care Med. 172(12), 1497-1504 (2005).
29. Rasenack N, Müller BW. Micron-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 9(1), 1-13 (2004).
30. Wittmann R, Schwarz E, Steckel H. The Influence of Amorphous Content in Lactose on the De-agglomeration Behavior of Powders for Inhalation. Presented at: Drug Delivery To The Lungs 23: Proceedings. Edinburgh, UK, 5-7 December 2012.
31. Mackin L, Zanon R, Park JM, Foster K, Opalenik H, Demonte M. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int. J. Pharm. 231(2), 227236 (2002).
32. Young PM, Chiou H, Tee T et al. The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders. Drug Dev. Ind. Pharm. 33(1), 91-97 (2007).
33. Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R. Investigation into the influence of primary crystallization conditions on the mechanical properties and secondary processing behaviour of fluticasone propionate for carrier based dry powder inhaler formulations. Pharm. Res. 29(4), 994-1006 (2012).
34. Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation. Int. J. Pharm. 430(1-2), 26-33 (2012).
35. Steckel H, Brandes HG. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 278(1), 187-195 (2004).
36. Littringer EM, Mescher A, Schröttner H, Achelis L, Walzel P, Urbanetz NA. Spray dried mannitol carrier particles with tailored surface properties -the influence of carrier surface roughness and shape. Eur. J. Pharm. Biopharm. 82(1), 194-204 (2012).
37. Littringer EM, Mescher A, Eckhard S et al. Spray drying of mannitol as a drug carrier -the impact of process parameters on product properties. Drying Technol. 30(1), 114-124 (2012).
38. Chan H, Chew NY. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv. Drug Deliv. Rev. 55(7), 793-805 (2003).
39. Weers J, Clark A, Challoner Peter. High dose inhaled powder delivery: challenges and techniques. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Virginia Commonwealth University, VA, USA, 281-288 (2004).
40. Weers J, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv. 4(3), 297-313 (2007).
41. Jin TH, Tsao E, Goudsmit J, Dheenadhayalan V, Sadoff J. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine 28(27), 4369-4375 (2010).
42. Maa Y, Nguyen P, Sweeney T, Shire S, Hsu C. Protein inhalation powders: spray drying vs spray freeze drying. Pharm. Res. 16(2), 249-254 (1999).
43. Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 305(1-2), 180-185 (2005).
44. Costantino HR, Firouzabadian L, Hogeland K et al. Protein spray-freeze drying. effect of atomization conditions on particle size and stability. Pharm. Res. 17(11), 1374-1382 (2000).
45. Costantino HR, Firouzabadian L, Wu C et al. Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. J. Pharm. Sci. 91(2), 388-395 (2002).
46. Johnson OL, Jaworowicz W, Cleland J et al. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14(6), 730-735 (1997).
47. Saluja V, Amorij J, Kapteyn J, Boer De AH, Frijlink HW, Hinrichs W. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J. Control. Release 144(2), 127-133 (2010).
48. Steckel H, Thies J, Müller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm. 152(1), 99-110 (1997).
49. Shekunov BY, Chattopadhyay P, Seitzinger J. Supercritical Fluid Processing Techniques -Comparing Supercritical fluid processing techniques: comparing the products. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Virginia Commonwealth University, VA, USA (2004).
50. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm. Res. 24(3), 411-437 (2007).
51. Shekunov BY, Feeley JC, Chow AHL, Tong HH, York P. Aerosolisation behaviour of micronised and supercriticallyprocessed powders. J. Aerosol Sci. 34(5), 553-568 (2003).
52. Lobo JM, Schiavone H, Palakodaty S, York P, Clark A, Tzannis ST. SCF-engineered powders for delivery of budesonide from passive DPI devices. J. Pharm. Sci. 94(10), 2276-2288 (2005).
53. Kellermann: US20110171141 A1 (2010).
54. Hersey JA. Ordered mixing: A new concept in powder mixing practice. Powder Technol. 11(1), 41-44 (1975).
55. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 270(1-2), 297-306 (2004).
56. Tee S, Marriott C, Zeng X, Martin G. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int. J. Pharm. 208(1-2), 111-123 (2000).
57. Rahimpour Y, Kouhsoltani M, Hamishehkar H. Alternative carriers in dry powder inhaler formulations. Drug Discov. Today (2013).
58. Kaialy W, Nokhodchi A. Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler. Pharm. Res. 30(2), 458-477 (2013).
59. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1-2), 1-19 (2010).
60. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir. Care 50(9), 1209-1227 (2005).
61. Grasmeijer F, Hagedoorn P, Frijlink HW, Boer De AH. Drug content effects on the dispersion performance of adhesive mixtures for inhalation. PLoS ONE 8(8), e71339 (2013).
62. Traini D, Young PM, Thielmann F, Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in dpi formulations. Drug Dev. Ind. Pharm. 34(9), 992-1001 (2008).
63. Young PM, Edge S, Triani D et al. The influence of dose on the performance of dry powder inhalation systems. Int. J. Pharm. 296(1-2), 26-33 (2005).
64. Staniforth JN. Performance-modifying influences in dry powder inhalation systems. Aerosol Sci. Technol. 22(4), 346-353 (1995).
65. Staniforth JN. Pre-formulation aspects of dry powder aerosols. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, Inc., IL, USA, 65-73 (1996).
66. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res. 15(4), 562-569 (1998).
67. Lucas P, Clarke MJ, Anderson K, Tobyn MJ, Staniforth JN. The role of fine particle excipients in pharmaceutical dry powder aerosoles. In: Respiratory drug delivery VI. Dalby RN, Byron PR, Farr SJ (Eds). VA, USA, 243-250 (1998).
68. Cordts E, Steckel H. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance. Eur. J. Pharm. Biopharm. 82(2), 417-423 (2012).
69. Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm. Res. 23(8), 1665-1674 (2006).
70. Dickhoff BHJ, de Boer AH, Lambregts D, Frijlink HW. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation. Int. J. Pharm. 327(1-2), 17-25 (2006).
71. Shur J, Harris H, Jones MD, Kaerger J, Price R. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm. Res. 25(7), 1631-1640 (2008).
72. de Boer AH. Interactions in adhesive mixture dispersion. Presented at: Lactose as a Carrier for Inhalation Products. Parma, Italy, 28 September 2010.
73. Boer De AH, Chan H, Price R. A critical view on lactosebased drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv. Drug Deliv. Rev. 64(3), 257-274 (2012).
74. Boer De AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. Air classifier technology (ACT) in dry powder inhalation: Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm. 260(2), 187-200 (2003).
75. Cordts E, Grasmeijer F, van der Wel P, Dekens B, Boer De AH, Steckel H. The influence of mixing time and intensity on blend homogeneity and dispersion performance. Presented at: Drug Delivery To The Lungs 23: Proceedings. Edinburgh, UK, 5-7 December 2012.
76. Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting 2-agonists. Curr. Pharm. Des. 12(25), 3261-3279 (2006).
77. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol. 112(1), 29-36 (2003).
78. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst. Rev. 4, CD005533 (1996).
79. Seyfang K, Steckel H. Pulverabfüllung: Kleine Mengen richtig dosieren. TechnoPharm 3(6), 304-311 (2013).
80. Powder Flow. In: The United States Pharmacopeia: The National Formulary. The United States Pharmacopeial Convention, MD, USA (2013).
81. Freeman T, Seyfang K. Enhancing dose consistency. Manufacturing Chemist Pharma, 13 March (2010).
82. Eskandar F, Lejeune M, Edge S. Low powder mass filling of dry powder inhalation formulations. Drug Dev. Ind. Pharm. 37(1), 24-32 (2011).
83. Chen X, Seyfang K, Steckel H. Development of a micro dosing system for fine powder using a vibrating capillary. Part 1: The investigation of factors influencing on the dosing performance. Int. J. Pharm. 433(1-2), 34-41 (2012).
84. Chen X, Seyfang K, Steckel H. Development of a microdosing system for fine powder using a vibrating capillary. Part 2. The implementation of a process analytical technology tool in a closed-loop dosing system. Int. J. Pharm. 433(1-2), 42-50 (2012).
85. Son Y, McConville JT. Advancements in dry powder delivery to the lung. Drug Dev. Ind. Pharm. 34(9), 948-959 (2008).
86. White S, Bennett DB, Cheu S et al. EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 7(6), 896-906 (2005).
87. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv. Drug Deliv. Rev. 58(9-10), 1061-1075 (2006).
88. Donovan MJ, Gibbons A, Herpin MJ, Marek S, McGill SL, Smyth HDC. Novel dry powder inhaler particle-dispersion systems. Ther. Deliv. 2(10), 1295-1311 (2011).
89. Islam N, Gladki E. Dry powder inhalers (DPIs) -a review of device reliability and innovation. Int. J. Pharm. 360(1-2), 1-11 (2008).
90. Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 7(12), 1359-1372 (2010).
91. Aerosoles, nasal sprays, meterd-dose inhalers; and dry powder inhalers. In: The United States Pharmacopeia: The National Formulary. The United States Pharmacopeial Convention, MD, USA (2013).
92. Zubereitungen zur Inhalation -Inhalanda. In: Europäisches Arzneibuch: amtliche deutsche Ausgabe, 7th Edition, Dt. Apotheker-Verl., Stuttgart, Germany (2011).
93. Frijlink HW, Boer De AH. Trends in the technology-driven development of new inhalation devices. Drug Discov. Today: Technol. 2(1), 47-57 (2005).
94. Zubereitungen zur Inhalation: Aerodynamische Beurteilung feiner Teilchen. In: Europäisches Arzneibuch: amtliche deutsche Ausgabe, 7th Edition, Dt. Apotheker-Verl., Stuttgart, Germany (2011).
95. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol Med. 16(4), 341-377 (2003).
96. Miller NC, Maniaci MJ, Dwivedi S, Ward GW. Aerodynamic sizing with simulated inhalation profiles: total dose capture and measurement. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Virginia Commonwealth University, VA, USA, 191-196 (2000).
97. Olsson B, Borgström L, Lundbäck H, Svensson M. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J. Aerosol Med. Pulm. Drug Deliv. 26(6), 355-369 (2013).
98. Boer De AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138(1), 45-56 (1996).
99. Borgström L. On the Use of Dry Powder Inhalers in Situations Perceived as Constrained. J. Aerosol Med. 14(3), 281-287 (2001).
100. Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today 3(7), 246-256 (2000).
101. Boer De AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW. Air classifier technology (ACT) in dry powder inhalation. Int. J. Pharm. 310(1-2), 72-80 (2006).
102. Boer De AH, Bolhuis G, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Int. J. Pharm. 153(1), 67-77 (1997).
103. Weers J, Ung K, Le J et al. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subjects inhalation Maneuver. J. Aerosol Med. Pulm. Drug Deliv. 26(1), 56-68 (2013).
104. Price R, Young PM, Edge S, Staniforth J. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm. 246(1-2), 47-59 (2002).
105. Zhu K, Tan RB, Kiong Ng W, Shen S, Zhou Q, Heng PW. Analysis of the influence of relative humidity on the moisture sorption of particles and the aerosolization process in a dry powder inhaler. J. Aerosol Sci. 39(6), 510-524 (2008).
106. Jashnani RN, Byron PR, Dalby RN. Testing of dry powder aerosol formulations in different environmental conditions. Int. J. Pharm. 113(1), 123-130 (1995).
107. Young PM, Price R. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur. J. Pharm. Sci. 22(4), 235-240 (2004).